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Abstract
Objective: The study was conducted to determine the prevalence of red 
blood cell alloantibodies for transfused patients in the East Taiwanese 
population.
Materials and Methods: We analyzed the clinical and transfusion records 
of 15,794 individuals who received transfusions in Hualien Tzu Chi Hospital 
from 2004 to 2006. Blood samples were subjected to standard blood 
bank procedures for screening for antibodies.
Results: Of the 15,794 transfused patients, 538 patients (3.39%) were 
found to have alloantibodies. Among these 538 patients, 333 patients were 
found to carry alloantibodies at the initial transfusion (2.0%) and 205 
(1.3%) patients developed alloantibodies during the transfusion period.
Conclusion: Our data demonstrate that anti-Mia was the most frequently 
detected alloantibody in the Eastern Taiwanese population, with an inci-
dence (1.5%) that was higher than reported in other Taiwanese populations. 
[Tzu Chi Med J 2009;21(1):66−69]
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1. Introduction
Alloimmunity against erythrocyte antigens is one of 
the major complications of transfusions, particularly 
in patients who are chronically transfused. This type 
of sensitization results in difficulty in obtaining com-
patible blood, reactions to transfusions, hemolysis and 
occasionally life-threatening adverse events. With the 
exception of ABO and Rh(D), there is little information 
about the distribution of blood groups among Chinese 
people [1]. Alloantibody screening is included in routine 
blood compatibility testing in Taiwan.
Formation of alloantibodies against red blood cells 
(RBCs) has been well documented in previous studies 
[2−4]. Alloantibodies are directed against the individ-
ual’s own RBCs, which can result in clinical hemolysis 
and difficulty in cross-matching blood. Most alloanti-
bodies react with high incidence antigens, causing 
agglutination and sensitization to RBCs from random 
donors as well as those of antibody producers. These 
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circulating humoral antibodies may shorten the du-
ration of RBC survival [5]. Patients with alloantibodies 
may have higher transfusion rates and often require 
immunosuppressive drugs, splenectomy, or alternative 
treatments in place of transfusions.
There have been few large-scale studies of erythro-
cyte alloantibodies in patients from Eastern Taiwan. In 
this paper, we evaluated the frequency of alloantibod-
ies for patients from the East Taiwanese population.
2. Materials and methods
In Taiwan, pretransfusion testing consists of ABO 
grouping, antibody screening and major cross match-
ing. From 2004 to 2006, antibody screening and 
cross-matching were performed on 15,794 consecu-
tive patients in Hualien Tzu Chi Hospital using the 
manual hexadimethrine bromide method. We analyzed 
transfusion records of these patients for this study. 
We identified all antibodies from positive antibody 
screening tests or incompatible cross-matches and 
calculated the incidence of clinically significant allo-
antibodies. The χ2 test was performed to test for gen-
der and age-group homogeneity in this group. The 
level of signi ficance was set at 0.05 for each test. All 
analyses were carried out using SPSS version 13.0 
(SPSS Inc., Chicago, IL, USA).
3. Results
A total of 15,794 transfused patients were included 
in our study. The clinically significant alloantibodies 
identified in our blood bank over the 3-year period are 
shown in Table 1. A total of 538 patients (538/15,794, 
3.39%) were found to have alloantibodies. Among this 
group of patients, 329 patients (2.0%) were found to 
Table 1 — Alloantibodies detected in patients transfused at Hualien Tzu Chi Hospital from 2004 to 2006
Alloantibody
 First Secondary Total
 (n = 329) (n = 212) (n = 538)
    n % n % n %
c    3 0.91 1 0.47 4 0.74
e    6 1.82 5 2.36 11 2.04
C    1 0.30 0 0.00 1 0.19
D    3 0.91 0 0.00 3 0.56
Dia    3 0.91 3 1.42 6 1.12
E    42 12.77 42 19.81 84 15.61
I    0 0.00 2 0.94 2 0.37
JKa    2 0.61 3 1.42 5 0.93
JKb    0 0.00 1 0.47 1 0.19
Lea    24 7.29 20 9.43 44 8.18
Leb    3 0.91 4 1.89 7 1.30
M    16 4.86 7 3.30 23 4.28
Mia    181 55.02 58 27.36 239 44.42
PI    10 3.04 13 6.13 23 4.28
e C   1 0.30 4 1.89 5 0.93
C e Mia  1 0.30 0 0.00 1 0.19
E c   20 6.08 19 8.96 39 7.25
E c JKa  0 0.00 1 0.47 1 0.19
E c Mia  4 1.22 2 0.94 6 1.12
E c Mia E 0 0.00 1 0.47 1 0.19
E c Mia autoAb 0 0.00 1 0.47 1 0.19
E c Mia P1 0 0.00 1 0.47 1 0.19
E c S Fyb 1 0.30 1 0.47 1 0.19
E JKa   0 0.00 1 0.47 1 0.19
E JKb   1 0.30 1 0.47 1 0.19
E Lea   0 0.00 1 0.47 1 0.19
E M   0 0.00 1 0.47 1 0.19
E P1   0 0.00 1 0.47 1 0.19
E Mia   3 0.91 9 4.25 12 2.23
E Mia Dia  0 0.00 1 0.47 1 0.19
E Mia M  0 0.00 1 0.47 1 0.19
E Mia autoAb  0 0.00 1 0.47 1 0.19
Lea Dia   1 0.30 1 0.47 1 0.19
Lea Leb   1 0.30 2 0.94 3 0.56
Lea P1   0 0.00 1 0.47 1 0.19
Mia N   0 0.00 2 0.94 2 0.37
Mia JKa   1 0.30 0 0.00 1 0.19
autoAb E   1 0.30 0 0.00 1 0.19
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carry alloantibodies at the time of initial transfusion. 
A total of 212 patients (1.3%) subsequently developed 
alloantibodies during the transfusion period, indicat-
ing the frequency of recent alloimmunization. During 
the initial transfusion (Table 1), the anti-Mia alloanti-
body was observed most frequently (55.02%). The 
least common alloantibody, anti-C, was found in only 
one person. Anti-I and anti-JKb alloantibodies were 
not observed. In patients with multiple alloantibodies, 
anti-E and anti-(c) were most frequently detected.
With alloimmunization secondary to transfusion 
(Table 1), anti-Mia was observed most frequently 
(27.36%). However, the frequency of the alloantibody 
anti-E was increased to 19.81%. The least common 
types were anti-(c) and anti-JKb. In patients with mul-
tiple alloantibodies, anti-E and anti-(c) were observed 
most frequently (8.96%).
Demographic variables, including gender and age 
group, are shown in Table 2. Gender distribution was 
homogeneous, with no significant differences in the 
frequency of the most common alloantibody types 
between males and females at the time of initial trans-
fusion (Table 3). However, the frequency of alloanti-
body detection was significantly different between age 
groups. In particular, alloantibody frequency in patients 
aged 61−80 years (43.49%) was noticeably higher than 
in the other age groups. To illustrate this, we have 
listed in Table 3 the frequencies of four common al-
loantibody types (anti-E, anti-Lea, anti-Mia, and the 
most frequent multiple alloantibody combination of 
anti-E and -(c)) according to gender and age group. 
Only the anti-Lea alloantibody was not significantly 
different among the five age groups. For the second 
transfusion assessment, the frequency of anti-Mia de-
tection in males was greater than that in females, 
while the other three common alloantibody types were 
homogeneous (Table 4). Interestingly, the distribution 
of anti-E and anti-(c) was also homogeneous among 
the five age groups.
4. Discussion
In the past, routine pretransfusion testing in Taiwan 
included only ABO grouping and room-temperature 
major and minor cross-matches, mostly done by a 
slide method. Overt hemolytic transfusion reactions 
were almost exclusively a result of ABO mismatches. 
Even though antibody screening has been introduced 
in recent years as an essential part of compatibility 
testing, clinically significant alloantibodies were en-
countered comparatively more frequently, ranging from 
3.55% in the East Taiwanese population to 2.1% at 
Mackay Memorial Hospital [6]. In our investigation, at 
both the initial and second transfusion assessments 
a single alloantibody was found most frequently. This 
includes 239 cases with anti-Mia of 538 patients with 
alloantibodies. Therefore the frequency of anti-Mia 
among transfused patients was 1.5% (239/15,794), 
higher than the 1.2% noted at Mackay Memorial Hospital 
[6]. The significance of this finding is unclear given 
the limited data on the transfusion recipients in the 
study, including data on the heterogeneity of ethnic-
ity, multiple transfusions, and frequency of different 
diseases. Anti-Mia has been observed with greater fre-
quency in children than in adults [7]. This age bias has 
Table 2 — Demographic data of 538 patients
Demographic data Patients, n (%) p*
Gender  0.49
 Male 277 (51.49)
 Female 261 (48.51)
Age (yr)  < 0.001
 1−20 11 (2.04)
 21−40 66 (12.27)
 41−60 177 (32.9)
 61−80 234 (43.49)
 81−100 50 (9.3)
*Obtained using the χ2 test of homogeneity.
Table 3 — Gender and age differences in the most 
common alloantibody types at first transfusion
 anti-E anti-Lea anti-Mia anti-E/c
 (n = 42) (n = 24) (n = 181) (n = 20)
Gender
 Male 20 13 87 13
 Female 22 11 94  7
 p* 0.758 0.683 0.603 0.18
Age (yr)
 1−20  1  0  3  0
 21−40  3  5 19  3
 41−60 15 10 63 10
 61−80 19  7 77  6
 81−100  4  2 19  1
 p* < 0.001 0.129 < 0.001 0.027
*Obtained using the χ2 test of homogeneity. Anti-E/c = detection of 
both anti-E and anti-(c) antibodies.
Table 4 — Gender and age differences in the most 
common alloantibody types at second transfusion
 anti-E anti-Lea anti-Mia anti-E/c
 (n = 42) (n = 20) (n = 58) (n = 19)
Gender
 Male 20 14 38  7
 Female 22  6 20 12
 p* 0.758 0.074 0.018 0.251
Age (yr)
 1−20  1  1  2  1
 21−40  5  3  8  3
 41−60 13  4 15  6
 61−80 24 10 28  5
 81−100  2  2  5  4
 p* < 0.001 0.014 < 0.001 0.42
*Obtained using the χ2 test of homogeneity. Anti-E/c = detection of 
both anti-E and anti-(c) antibodies.
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been postulated to be due to bacterial infections within 
the pediatric age range.
The term anti-Mia is used throughout this report to 
describe those antibodies in our patients’ sera that 
react with antibody-screening cells of the Mi III phe-
notype. Anti-Mia appears to be an alloantibody of po-
tential clinical significance in Taiwan and, therefore, 
it may be important that Mi III RBCs are included in 
the antibody screening cells used in blood banks in 
Taiwan. In fact, this has been the situation since July 
1990. Because patients expressing anti-Mia may have 
a history of blood transfusion or pregnancy, anti-Mia 
may occur either naturally or as a result of immuni-
zation in these patients.
In our study, the second most common single allo-
antibody was anti-E (0.53%, 84/15,794). Before routine 
screening for anti-Mia was instituted, the frequency of 
alloantibodies of potential clinical significance that were 
detected among Chinese patients at Mackay Memorial 
Hospital between 1984 and 1987 was found to be 
0.146%, with anti-E being the most common single 
specificity [1,8].
Among patients with multiple alloantibodies, anti-
E and anti-(c) were found to be the most common in 
primary and secondary alloimmunization. This result 
is similar to the results of other studies [1,9]. The op-
portunity for immunization to both E and c is very sim-
ilar in both Chinese and Caucasians, although the most 
common alloantibodies, anti-E and anti-(c), occur much 
less frequently among Chinese than in Caucasians. 
Therefore, we hypothesize that the reaction to red cell 
antigenic stimulus is worse amongst Chinese patients 
than amongst Caucasians.
In our study, patient gender did not impact the 
frequencies of alloantibodies against red blood cell 
antigens. The greater prevalence of alloimmunization 
among females, with a male:female ratio of 1:2.7, is 
similar to the 1:2 ratio reported by some [10,11], but 
not all [12,13], studies. Possible explanations for the 
increased antibody prevalence in females may include 
previous exposure through pregnancy, greater immune 
response in women, and greater exposure of women 
through transfusion.
However, at the second transfusion, anti-Mia was 
more frequent in males than in females in this study. 
The reason for this difference is not clear. Blumberg 
et al [11] reported a male:female alloimmunization 
ratio of 1:2 before transfusion, but they also reported 
a 2:1 ratio for the development of new antibodies 
during transfusion. These findings suggest that an 
enhanced immune response is not the cause of the 
observed female predominance, because the frequency 
of alloimmunization after transfusion was equivalent 
[12,13] or greater [11] in males.
When age was taken into account, there were sig-
nificant differences in the frequency of alloantibody 
detection. Specifically, the frequency of alloantibodies 
in patients aged 61−80 years (43.49%) was higher 
than that of other groups. When considering the com-
mon alloantibodies (anti-E, anti-Lea, anti-Mia) and one 
multiple alloantibody (anti-E and anti-(c)), transfusion 
recipient age was a dominant factor in the initial and 
secondary transfusion (p < 0.001), with the exception 
of anti-Lea and multiple alloantibody detection. This 
interesting observation in our study may be related 
to greater exposure and immunization with age.
In summary, this study shows that red blood cell 
alloantibodies are a frequent finding amongst patients 
in the East Taiwanese population. Several factors might 
have contributed to this finding, including the het-
erogeneity of the population, increased frequency of 
transfusion, and population exposure to different dis-
eases. It should be noted that potential selection bias 
may influence the calculations and results discussed 
above. For these reasons, further investigation is re-
quired in order to prevent alloimmunization in patients 
requiring chronic transfusion therapy.
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